References
- The WHO-IUALTD. Anti-tuberculosis drug resistance in the world. World Health Organization, Geneva, 1997.
- Truffolt-Pernot JB, Grosset J. In vitro and in vivo activi-ties of sparfloxacin against mycobacterium tuberculosis. Tubercle 1991; 72 (3): 181-6.
- Hoffner SE, Gezelius L, Olsson-Liliüjequist B. In vitro activities of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1997; 40 (6): 885–8.
- Gillespie SH. Preclinical microbiology: mycobacteria. In: First International Moxifloxacin Symposium. By L. Mandell, Berlin: Springer Verlag, 1999: 37-41.
- Lounis N, Masio C, Truffolt-Permnot C, Bonnafous O, Grosset J. In vitro and in vivo activities of moxifloxacin against mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42 (8): 2066–9.
- Lounis N, Bentoucha A, Truffolt-Pernot C, et al. Effectiveness of once-weekly rifapentine and moxifloxacin reg-imens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001; 45 (12): 3482–6.
- Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin, a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999; 43 (1): 85–9.